• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.1809年至2022年及以后的卵巢癌研究视角
Diagnostics (Basel). 2022 Mar 24;12(4):791. doi: 10.3390/diagnostics12040791.
2
Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative.当CA125检测结果无诊断价值时对早期卵巢恶性肿瘤的挽救性检测
Diagnostics (Basel). 2021 Aug 10;11(8):1440. doi: 10.3390/diagnostics11081440.
3
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.专家共识:晚期或转移性上皮性卵巢癌的评估和管理。
Rev Colomb Obstet Ginecol. 2024 Jun 14;75(1):4094. doi: 10.18597/rcog.4094.
4
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.一线新辅助卡铂-紫杉醇方案治疗卵巢、输卵管或原发性腹膜癌的客观反应(ICON8):一项随机、3 期试验的事后探索性分析。
Lancet Oncol. 2021 Feb;22(2):277-288. doi: 10.1016/S1470-2045(20)30591-X. Epub 2020 Dec 22.
5
Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India.印度东北部某地区癌症中心100例女性晚期高级别浆液性上皮性卵巢癌的批判性分析。
South Asian J Cancer. 2023 Aug 7;12(4):334-340. doi: 10.1055/s-0043-1771444. eCollection 2023 Oct.
6
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.高级别浆液性晚期卵巢癌的BRCA突变状态、初始疾病表现及临床结局:一项多中心研究
Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.
7
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
8
Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.血清人附睾蛋白4在预测上皮性卵巢癌手术预后较差方面优于癌抗原125。
Tumour Biol. 2016 Nov;37(11):14765-14772. doi: 10.1007/s13277-016-5335-0. Epub 2016 Sep 15.
9
Epithelial Ovarian Cancer上皮性卵巢癌
10
Differential blood count as triage tool in evaluation of pelvic masses.鉴别血球计数作为评估骨盆腔肿块的分诊工具。
Int J Gynecol Cancer. 2021 May;31(5):733-743. doi: 10.1136/ijgc-2019-001103. Epub 2020 Jun 2.

引用本文的文献

1
Histopathology and indicators of borderline ovarian tumours with microinvasion in bitches.母犬微小浸润性卵巢交界性肿瘤的组织病理学及指标
Vet Med (Praha). 2023 Apr 12;68(4):175-183. doi: 10.17221/103/2022-VETMED. eCollection 2023 Apr.
2
Antioxidant, and Ovarian Anticancer Activity (Ovarian Cancer Cells-PA1) and Phytochemical Analysis of L. Ethanolic Extract.抗氧化剂及其对卵巢癌细胞(PA1)的抗癌活性和 L. 乙醇提取物的植物化学成分分析。
Comb Chem High Throughput Screen. 2024;27(10):1504-1512. doi: 10.2174/0113862073255558230926114444.
3
Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?BRCA 突变携带者的激素替代疗法:我们如何做到不造成伤害?
Hormones (Athens). 2023 Mar;22(1):19-23. doi: 10.1007/s42000-022-00427-1. Epub 2023 Jan 13.
4
Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition.铂耐药卵巢癌易受cJUN-XRCC4通路抑制的影响。
Cancers (Basel). 2022 Dec 9;14(24):6068. doi: 10.3390/cancers14246068.
5
Molecular Management of High-Grade Serous Ovarian Carcinoma.高级别浆液性卵巢癌的分子管理
Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777.
6
ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models.ODF2L 在卵巢上皮性癌细胞模型中与 WEE1 抑制作用协同致死。
J Clin Invest. 2023 Jan 17;133(2):e161544. doi: 10.1172/JCI161544.
7
Recurrence and 5-year survival rate in patients with borderline ovarian tumors and related factors in Kurdistan.库尔德斯坦地区卵巢交界性肿瘤患者的复发率、5年生存率及相关因素
Eur J Transl Myol. 2022 Sep 29;33(1):10779. doi: 10.4081/ejtm.2022.10779.

本文引用的文献

1
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).帕福拉西尼注射液(OTL38)用于叶酸受体阳性卵巢癌术中成像的III期研究(研究006)。
J Clin Oncol. 2023 Jan 10;41(2):276-284. doi: 10.1200/JCO.22.00291. Epub 2022 Sep 7.
2
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.奥拉帕利治疗 BRCA 突变和同源重组缺陷状态的铂敏感复发性卵巢癌:LIGHT 研究 II 期初步分析。
Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5.
3
Low-Grade Serous Carcinoma of the Ovary: The Current Status.卵巢低级别浆液性癌:现状
Diagnostics (Basel). 2022 Feb 10;12(2):458. doi: 10.3390/diagnostics12020458.
4
Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.HE4、CA125、ROMA和CPH-I用于附件肿瘤术前评估的比较
Diagnostics (Basel). 2022 Jan 17;12(1):226. doi: 10.3390/diagnostics12010226.
5
Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram.经阴道超声检查在卵巢癌筛查中观察到盆腔积液的意义。
Diagnostics (Basel). 2022 Jan 7;12(1):144. doi: 10.3390/diagnostics12010144.
6
Ultrasonographic Visualization of the Ovaries to Detect Ovarian Cancer According to Age, Menopausal Status and Body Type.根据年龄、绝经状态和体型,通过超声检查卵巢以检测卵巢癌
Diagnostics (Basel). 2022 Jan 6;12(1):128. doi: 10.3390/diagnostics12010128.
7
Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance.使用种系 BRCA 检测对患有卵巢癌和商业保险的患者进行检测。
JAMA Netw Open. 2022 Jan 4;5(1):e2142703. doi: 10.1001/jamanetworkopen.2021.42703.
8
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.在 III 期 PAOLA-1/ENGOT-ov25 试验中,根据新诊断的晚期卵巢癌患者的临床风险,维持奥拉帕利联合贝伐珠单抗的疗效。
Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22.
9
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.随机化试验:细胞减灭术治疗复发性卵巢癌。
N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294.
10
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.奥拉帕利维持治疗新诊断的 BRCA 突变晚期卵巢癌患者(SOLO1/GOG 3004):一项随机、双盲、安慰剂对照、III 期临床试验的 5 年随访。
Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26.

1809年至2022年及以后的卵巢癌研究视角

Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.

作者信息

Lawton Frank G, Pavlik Edward J

机构信息

Gynaecological Cancer Surgeon South East London Gynaecological Cancer Centre, Guy's and St Thomas' NHS Trust, London SE1 7EH, UK.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536, USA.

出版信息

Diagnostics (Basel). 2022 Mar 24;12(4):791. doi: 10.3390/diagnostics12040791.

DOI:10.3390/diagnostics12040791
PMID:35453839
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9024743/
Abstract

Unlike many other malignancies, overall survival for women with epithelial ovarian cancer has improved only modestly over the last half-century. The perspectives presented here detail the views of a gynecologic oncologist looking back and the view of the academic editor looking forward. Surgical beginnings in 1809 are merged with genomics, surgical advances, and precision therapy at present and for the future. Presentations in this special issue focus on factors related to the diagnosis of ovarian cancer: (1) markers for the preoperative assessment of primary and metastatic ovarian tumors, (2) demonstrations of the presence of pelvic fluid in ultrasound studies of ovarian malignancies, (3) the effects of age, menopausal status, and body habitus on ovarian visualization, (4) the ability of OVA1 to detect ovarian cancers when Ca125 was not informative, (5) the detection of tumor-specific changes in cell adhesion molecules by tissue-based staining, (6) presentation of a high discrimination model for ovarian cancer using IOTA Simple Rules and CA125, (7) review of low-grade serous carcinoma of the ovary, and (8) a comprehensive case report on ovarian carcinosarcoma.

摘要

与许多其他恶性肿瘤不同,上皮性卵巢癌女性患者的总体生存率在过去半个世纪中仅略有提高。此处呈现的观点详细阐述了一位妇科肿瘤学家的回顾性看法以及学术编辑的前瞻性看法。1809年的外科手术开端与当前及未来的基因组学、手术进展和精准治疗相结合。本期特刊的文章聚焦于与卵巢癌诊断相关的因素:(1)原发性和转移性卵巢肿瘤术前评估的标志物;(2)卵巢恶性肿瘤超声检查中盆腔积液存在情况的展示;(3)年龄、绝经状态和体型对卵巢可视化的影响;(4)当Ca125无诊断价值时OVA1检测卵巢癌的能力;(5)通过组织染色检测细胞黏附分子中肿瘤特异性变化;(6)使用IOTA简单规则和CA125的卵巢癌高鉴别模型介绍;(7)卵巢低级别浆液性癌综述;(8)卵巢癌肉瘤综合病例报告。